WO2021006684A1 - Method for preparation of ultrasonicated yeast extract having excellent inhibitory activity against skin cancer and skin cancer-inhibiting composition comprising ultrasonicated yeast extract prepared by same method - Google Patents
Method for preparation of ultrasonicated yeast extract having excellent inhibitory activity against skin cancer and skin cancer-inhibiting composition comprising ultrasonicated yeast extract prepared by same method Download PDFInfo
- Publication number
- WO2021006684A1 WO2021006684A1 PCT/KR2020/009065 KR2020009065W WO2021006684A1 WO 2021006684 A1 WO2021006684 A1 WO 2021006684A1 KR 2020009065 W KR2020009065 W KR 2020009065W WO 2021006684 A1 WO2021006684 A1 WO 2021006684A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- skin cancer
- ultrasonic
- yeast
- yeast extract
- extract
- Prior art date
Links
- 208000000453 Skin Neoplasms Diseases 0.000 title claims abstract description 71
- 201000000849 skin cancer Diseases 0.000 title claims abstract description 68
- 229940041514 candida albicans extract Drugs 0.000 title claims abstract description 52
- 239000012138 yeast extract Substances 0.000 title claims abstract description 52
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 238000000034 method Methods 0.000 title claims description 18
- 230000002401 inhibitory effect Effects 0.000 title abstract description 24
- 239000002537 cosmetic Substances 0.000 claims abstract description 15
- 230000002265 prevention Effects 0.000 claims abstract description 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 102
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 48
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 48
- 239000000284 extract Substances 0.000 claims description 44
- 239000004480 active ingredient Substances 0.000 claims description 24
- 201000001441 melanoma Diseases 0.000 claims description 20
- 238000009210 therapy by ultrasound Methods 0.000 claims description 14
- 239000007864 aqueous solution Substances 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 239000000243 solution Substances 0.000 claims description 11
- 235000013305 food Nutrition 0.000 claims description 9
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 6
- 201000009030 Carcinoma Diseases 0.000 claims description 4
- 208000003154 papilloma Diseases 0.000 claims description 2
- 208000014212 sarcomatoid carcinoma Diseases 0.000 claims description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 230000035755 proliferation Effects 0.000 abstract description 6
- 235000013376 functional food Nutrition 0.000 abstract description 5
- 210000004027 cell Anatomy 0.000 description 27
- 230000000694 effects Effects 0.000 description 22
- 206010028980 Neoplasm Diseases 0.000 description 18
- 108010058546 Cyclin D1 Proteins 0.000 description 14
- 102000006311 Cyclin D1 Human genes 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 10
- 230000004663 cell proliferation Effects 0.000 description 10
- 230000001093 anti-cancer Effects 0.000 description 9
- 239000006071 cream Substances 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 238000002604 ultrasonography Methods 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 6
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000013543 active substance Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000000527 sonication Methods 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 239000012752 auxiliary agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 235000021067 refined food Nutrition 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 201000008261 skin carcinoma Diseases 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 210000003371 toe Anatomy 0.000 description 2
- 238000002137 ultrasound extraction Methods 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000173371 Garcinia indica Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 239000013040 bath agent Substances 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000013574 canned fruits Nutrition 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000008316 intracellular mechanism Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 235000015094 jam Nutrition 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011645 metastatic carcinoma Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- -1 pack Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000013324 preserved food Nutrition 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q90/00—Cosmetics or similar toiletry preparations for specific uses not provided for in other groups of this subclass
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/218—Yeast extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/48—Ultrasonic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/82—Preparation or application process involves sonication or ultrasonication
Definitions
- the present invention relates to a composition for improving, preventing or treating skin cancer comprising an ultrasonic yeast extract.
- Skin cancer increases the chance of exposure to various harmful substances or ultraviolet rays due to changes in life patterns such as increased outdoor activities and the increase in the amount of ultraviolet rays due to the destruction of the ozone layer due to environmental pollution. As the aging population increases, the number of patients continues to increase worldwide.
- basal cell carcinoma accounts for about 80%
- squamous cell carcinoma BCC
- SCC squamous cell carcinoma
- melanoma which corresponds to about 4%
- Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are collectively referred to as nonmelanoma skin cancer (NMSC).
- Melanoma arises from melanocytes in the epidermis, most of which are metastatic cancers or carcinomas that lead to death.In 2000, 47,000 people were identified as new melanomas, of which 7,700 were reported to have died (RT Greenlee et al. al. Cancer J. Clin., 50: 7-33, 2000).
- melanoma may be caused by chronic exposure to ultraviolet rays, but is expected to occur due to intermittent exposure such as extreme sun tanning. Because melanoma has a worse prognosis than other skin cancers, recurrence is common even if detected early and can shorten life. Skin lesions appear as yellowish brown or black spots or nodules, and usually occur after middle age by sun exposure. Sometimes it occurs in the ends of the hands and toes, especially the thumb and toe, and black vertical lines may be seen on the nails. In this case, melanoma should be suspected and a thorough investigation should be conducted.
- An object of the present invention is to provide a cosmetic composition for preventing or improving skin cancer comprising an ultrasonic yeast extract as an active ingredient.
- Another object of the present invention is to provide a food composition for preventing or improving skin cancer comprising an ultrasonic yeast extract as an active ingredient.
- Another object of the present invention is to provide a pharmaceutical composition for preventing or treating skin cancer comprising an ultrasonic yeast extract as an active ingredient.
- Another object of the present invention is to provide a method for preventing or treating skin cancer comprising administering a therapeutically effective amount of an ultrasonic yeast extract to an individual.
- Another object of the present invention is to provide the use of an ultrasonic yeast (yeast) extract to produce a pharmaceutical formulation having a preventive or therapeutic effect of skin cancer.
- yeast ultrasonic yeast
- Another object of the present invention is to provide a method for preparing an ultrasonic yeast extract comprising the step of adding an aqueous sodium hydroxide (NaOH) solution to yeast and treating ultrasonic waves.
- an aqueous sodium hydroxide (NaOH) solution to yeast and treating ultrasonic waves.
- the present invention provides a cosmetic composition for preventing or improving skin cancer comprising an ultrasonic yeast (yeast) extract as an active ingredient.
- yeast ultrasonic yeast
- the present invention provides a food composition for preventing or improving skin cancer comprising an ultrasonic yeast extract as an active ingredient.
- the present invention provides a pharmaceutical composition for preventing or treating skin cancer comprising an ultrasonic yeast extract as an active ingredient.
- the present invention provides a method for preventing or treating skin cancer comprising administering a therapeutically effective amount of an ultrasonic yeast extract to an individual.
- the present invention provides a method for preparing an ultrasonic yeast extract comprising the step of adding an aqueous sodium hydroxide (NaOH) solution to yeast and treating ultrasonic waves.
- aqueous sodium hydroxide (NaOH) solution to yeast and treating ultrasonic waves.
- the ultrasonic yeast extract according to the present invention has excellent activity of inhibiting the proliferation of skin cancer cells, and thus can be usefully used in the manufacture of cosmetics, functional foods and pharmaceuticals for the prevention, improvement or treatment of skin cancer.
- 1 is a result of analyzing the cell proliferation inhibitory ability of the yeast ultrasonic extract prepared according to each extraction condition for skin cancer cell lines.
- the present invention provides a composition for preventing, improving or treating skin cancer comprising an ultrasonic yeast extract as an active ingredient.
- the yeast may be Saccharomyces cerevisiae .
- the skin cancer is composed of melanoma, papilloma, carcinoma, squamous cell carcinoma, basal cell carcinoma, and spindle cell carcinoma. It may be selected from the group, but is not limited thereto.
- the present invention provides a method for producing an ultrasonic yeast extract having an activity capable of effectively inhibiting the proliferation of skin cancer cells.
- the yeast ultrasonic extract is prepared by treating yeast with ultrasonic waves.
- the ultrasonic extract of yeast obtained by performing the treatment of aqueous sodium hydroxide (NaOH) and ultrasonic treatment together has excellent skin cancer inhibitory activity.
- aqueous sodium hydroxide (NaOH) solution was added and It was confirmed that the extract obtained by ultrasonic treatment at 95° C. for 1.5 to 2.5 hours has the best skin cancer inhibitory activity.
- the present invention can provide a method for preparing an ultrasonic yeast extract having skin cancer inhibitory activity, and preferably, the method comprises adding 0.1M to 0.2M sodium hydroxide (NaOH) aqueous solution to the yeast, and 85°C to 95°C It may include the step of ultrasonic treatment for 1.5 hours to 2.5 hours.
- the method comprises adding 0.1M to 0.2M sodium hydroxide (NaOH) aqueous solution to the yeast, and 85°C to 95°C It may include the step of ultrasonic treatment for 1.5 hours to 2.5 hours.
- 0.2M sodium hydroxide (NaOH) aqueous solution is added to the yeast and ultrasonicated at 90° C. for 2 hours to obtain an ultrasonic yeast extract having excellent skin cancer inhibitory activity.
- the concentration of sodium hydroxide (NaOH) is less than 0.1M, there is a problem that extraction of an extract containing a physiologically active substance having skin cancer inhibitory activity from yeast is insufficient, whereas it exceeds 0.2M.
- the concentration of sodium hydroxide (NaOH) should be used in the range of 0.1M to 0.2M, and most preferably, the concentration of 0.2M can be used.
- the extraction temperature is performed at less than 85°C during the ultrasonic extraction of the present invention, as confirmed in an embodiment of the present invention, there is a problem that the skin cancer inhibiting activity of the ultrasonic yeast extract is insufficient, and at a temperature exceeding 95°C If performed, the active ingredient may be destroyed or denatured, which may also cause a decrease in skin cancer inhibitory activity.
- the extraction time may be performed in 1.5 hours to 2.5 hours.
- the ultrasonic yeast extract obtained by the method of the present invention has excellent anticancer activity against skin cancer.
- the ability to inhibit cell proliferation of the melanoma cell line was analyzed, and 0.2M sodium hydroxide (NaOH) aqueous solution was used.
- NaOH sodium hydroxide
- the present inventors analyzed the protein expression changes of c-myc and cyclin D1 in cells according to the treatment of the ultrasonic yeast extract of the present invention in order to determine through which mechanism the skin cancer inhibitory activity of the ultrasonic yeast extract of the present invention occurs. I did.
- the expression of c-myc in the group treated with the ultrasonic yeast extract of the present invention did not show any change in the expression level compared to the group not treated with the extract, but the expression level of the cyclin D1 protein was significantly decreased.
- the present invention provides a cosmetic composition for preventing or improving skin cancer comprising an ultrasonic yeast extract as an active ingredient.
- the composition may be prepared in a liquid or solid form using bases, auxiliary agents and additives commonly used in the cosmetic field.
- Cosmetics in a liquid or solid form may include, for example, but not limited to, a form such as a lotion, cream, lotion, and bath agent.
- the composition of the present invention may include not only an ultrasonic yeast extract, but also ingredients commonly used in cosmetic compositions, such as antioxidants, stabilizers, solubilizers, vitamins, pigments And conventional adjuvants such as fragrances, and carriers.
- ingredients commonly used in cosmetic compositions such as antioxidants, stabilizers, solubilizers, vitamins, pigments And conventional adjuvants such as fragrances, and carriers.
- the cosmetic composition of the present invention may be prepared in any formulation conventionally prepared in the art, for example, solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleaning, It may be formulated as an oil, powder foundation, emulsion foundation, wax foundation, and spray, but is not limited thereto. In more detail, it may be prepared in the form of a flexible lotion, nutritional lotion, nutritional cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray or powder.
- the present invention provides a food composition for preventing or improving skin cancer comprising an ultrasonic yeast extract as an active ingredient.
- a health food it can be prepared in the form of tea, juice, and drinks using the ultrasonic yeast extract of the present invention and consumed, or granulated, encapsulated, and powdered.
- it may be prepared in the form of a composition by mixing with known substances or active ingredients known to have an effect of preventing or improving skin cancer.
- functional foods include beverages (including alcoholic beverages), fruits and processed foods thereof (eg, canned fruit, canned food, jam, marmalade, etc.), fish, meat and processed foods thereof (eg, ham, sausage corn beef, etc.) ), breads and noodles (e.g. udon, soba, ramen, spaghetti, macaroni, etc.), fruit juice, various drinks, cookies, syrup, dairy products (e.g. butter, cheese, etc.), edible vegetable oil, margarine, vegetable protein, It can be prepared by adding the active ingredient of the present invention to retort foods, frozen foods, various seasonings (eg, miso, soy sauce, sauce, etc.).
- beverages including alcoholic beverages
- fruits and processed foods thereof eg, canned fruit, canned food, jam, marmalade, etc.
- fish e.g. ham, sausage corn beef, etc.
- breads and noodles e.g. udon, soba, ramen, spaghetti, macaroni, etc.
- fruit juice e
- the preferred content of the active ingredient of the present invention in the food composition of the present invention is not limited thereto, but may preferably be contained in a solid content of 0.01 to 50% by weight in the finally prepared food.
- the composition of the present invention may be prepared and used in the form of a powder or a concentrate.
- the present invention provides a pharmaceutical composition for preventing or treating skin cancer comprising an ultrasonic yeast extract as an active ingredient.
- the pharmaceutical composition is a tablet, capsule, pill, granule, powder, extract, suspension, emulsion, syrup, aerosol oral form, formulation, ointment, coating, or intravenous, intramuscular, subcutaneous, cerebrovascular It can be prepared in the form of a sterile injectable solution or suppository for administration.
- the pharmaceutical dosage form of the pharmaceutical composition of the present invention can be combined with an appropriate carrier that is generally acceptable for the manufacture of pharmaceutical compositions to be used in a conventional method. It can be formulated in various forms.
- Carriers, excipients and diluents that may be included in the pharmaceutical composition of the present invention include dextrose, lactose, sucrose, starch, sorbitol, mannitol, xylitol, gum acacia, calcium silicate, calcium phosphate, alginate, gelatin, cellulose , Methyl cellulose, microcrystalline cellulose, water, propylhydroxybenzoate, mineral oil, methylhydroxybenzoate, talc, magnesium stearate, and the like.
- it can be prepared by using diluents or excipients such as commonly used binders, disintegrants, fillers, extenders, surfactants, and wetting agents.
- Solid preparations for oral administration include tablets, capsules, pills, granules, powders, and the like, and these solid preparations contain at least one excipient, such as starch, sucrose or lactose, gelatin, etc. in the active ingredient of the present invention. It is prepared by mixing.
- Injections in the form of solutions or suspensions for parenteral administration may be administered subcutaneously, intravenously, intramuscularly, or intraperitoneally.
- the coating agent can be easily prepared in various forms such as cream, ointment, suspension, and emulsion according to a conventional manufacturing method.
- the active ingredient of the present invention is contained in a general water-in-water type or water-in-oil type base, and flavors, chelating agents, coloring agents, antioxidants, preservatives, etc. can be used as needed, and the purpose of improving physical properties Vitamins, proteins, minerals, etc. can be used in combination.
- the dosage of the active ingredient may be changed according to the weight of the patient, the severity of the disease, the drug formulation, the state of health, the route of administration, and the administration period. For a desirable effect, it is good to administer 0.001 to 10 g/kg per day, preferably 0.01 to 0.1 g/kg, but is not limited thereto. Administration can be administered once a day or divided into several times.
- the present invention provides a method for preventing or treating skin cancer comprising administering a therapeutically effective amount of an ultrasonic yeast extract to an individual.
- the therapeutically effective amount is a specific composition including the type and degree of the reaction to be achieved, whether or not other agents are used in some cases, the individual's age, weight, general health status, sex and diet, administration time, administration route and composition. It is preferable to apply differently depending on various factors including the secretion rate of the drug, the treatment period, drugs used with or concurrently with the specific composition, and similar factors well known in the medical field. Therefore, it is preferable to determine an effective amount of a composition suitable for the purposes of the present invention in consideration of the foregoing.
- the individual is applicable to any mammal, and the mammal includes humans and primates, as well as livestock such as cattle, pigs, sheep, horses, dogs and cats.
- the present invention provides the use of an ultrasonic yeast (yeast) extract to produce a pharmaceutical formulation having a preventive or therapeutic effect of skin cancer.
- yeast ultrasonic yeast
- the present inventors prepared an ultrasonic yeast extract by varying the following extraction conditions.
- an aqueous solution in which NaOH was dissolved in each concentration (0.15 and 0.2M) was added to yeast in powder form (Saccharomyces cerevisiae; purchased from Celltech Co., Ltd.) (10 times the amount of yeast (w/v)).
- yeast in powder form Sacharomyces cerevisiae; purchased from Celltech Co., Ltd.
- Addition) and hourly (1hr, 3hr, 5hr) ultrasonic treatment to prepare an ultrasonic extract, wherein the ultrasonic treatment conditions were 20 kHz, 80% amplitude, 750 W, pulse 20 s on/10 s off, and temperature was extracted by differently at 90°C, 70°C and 50°C, respectively.
- each yeast ultrasonic extract obtained in Example 1 was treated with each yeast ultrasonic extract, and then the degree of cell proliferation was analyzed.
- Each sample used in the cell proliferation analysis is shown in Table 1 below.
- B16F10 melanoma cell line was dispensed at 4 x 10 3 cells per well in a 96 well plate, and each ultrasonic extract was treated at various concentrations 3 hours after the cell dispensing, and then for 3 days under conditions of 37°C and 5% CO 2 During incubation. After incubation for 3 days, live cells were colored using Promega CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay (MTS) reagent to measure the degree of cell proliferation.
- MTS Non-Radioactive Cell Proliferation Assay
- the yeast ultrasonic extract (#2 ⁇ #13) obtained by ultrasonic treatment had a better inhibitory effect on the proliferation of melanoma cells compared to the control (control, #1) obtained by the alkaline extraction method without ultrasonic treatment.
- the yeast ultrasonic extracts (#10, #11) obtained by ultrasonic treatment at 90°C for 2 hours in 0.2M aqueous NaOH solution have a remarkable effect of inhibiting cell proliferation of melanoma cell lines compared to extracts obtained under other conditions. Confirmed (Fig. 1).
- the ultrasonic yeast extract of the present invention obtained under the above conditions was compared to the extract obtained using a 0.15M NaOH aqueous solution having a concentration lower than 0.2M and an extract obtained using a 0.5M NaOH aqueous solution having a concentration higher than 0.2M. It was confirmed that the cell proliferation inhibitory activity of skin cancer cell lines was remarkable.
- Example 2 From the results of Example 2, it was confirmed that the ultrasonic yeast extract has a remarkable effect on anticancer activity against skin cancer. Accordingly, the present inventors conducted an experiment to confirm the effect of the ultrasonic yeast extract on the intracellular mechanism on the inhibition of skin cancer.
- c-myc is known to be an oncogene
- Cyclin D1 is known to be overexpressed in cancer cells.
- the present inventors confirmed changes in the expression levels of c-myc and Cyclin D1 proteins in melanoma cell lines through Western blot when the yeast ultrasonic extract was treated.
- the ultrasonic yeast extract has the effect of remarkably suppressing the expression of the Cyclin D1 protein compared to the control (FIG. 2).
- the extract obtained by sonicating at 90°C for 2 hours in an aqueous NaOH solution of 0.15M and 0.2M concentration was obtained under different conditions (0.2M NaOH aqueous solution, 3 hours, ultrasonic treatment at 70°C; or 0.2M NaOH)
- Fig. 2 It was confirmed that there is an effect of remarkably suppressing the expression of Cyclin D1 protein compared to aqueous solution, 3 hours, sonication at 50°C)
- Fig. 2 there was no effect on the expression of c-myc (Fig. 2).
- the present inventors performed an experiment to analyze the tumor size and the expression level of Cyclin D1 in the tumor tissue by treating the ultrasonic yeast extract in an animal model. Briefly, 6 week old BALB/c-nu mice were used in the experiment, and mice were acclimated for 1 week after purchase. Thereafter, the B16F10 melanoma cell line (cell number: 5 ⁇ 10 5 cells) was injected into the dorsal skin tissue of each mouse. After confirming that tumors were formed in the dorsal skin tissue of the mouse, the yeast ultrasound extract (500 mg/kg body weight) was administered intraperitoneally once every 2 days. Tumor size was analyzed 0, 2, 4 and 6 days after administration of the yeast ultrasound extract, and changes in the expression of Cyclin D1 protein in the tumor tissue were measured by Western blot 6 days after administration of the yeast ultrasound extract.
- the present inventors confirmed that the ultrasonic yeast extract has a remarkable effect on anticancer activity even in an animal model of skin cancer.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to: a composition comprising an ultrasonicated yeast extract for prevention, alleviation, or treatment of skin cancer; and a preparation method therefor, wherein the ultrasonicated yeast extract has a remarkable inhibitory activity against the proliferation of skin cancer cells and can be advantageously used in cosmetic, functional food, and medicinal fields.
Description
본 발명은 효모 초음파 추출물을 포함하는 피부암의 개선, 예방 또는 치료용 조성물에 관한 것이다.The present invention relates to a composition for improving, preventing or treating skin cancer comprising an ultrasonic yeast extract.
피부암은 야외활동 증가와 같은 생활 패턴의 변화 및 환경오염에 따른 오존층의 파괴로 인한 자외선의 유입량 증가로 인해 각종 유해물질이나 자외선의 노출 기회가 빈번해지고, 인간의 평균수명이 늘어나면서 자외선 축적량이 많은 고령 인구수가 늘어남에 따라, 그 환자수가 전 세계적으로 지속해서 증가하고 있다.Skin cancer increases the chance of exposure to various harmful substances or ultraviolet rays due to changes in life patterns such as increased outdoor activities and the increase in the amount of ultraviolet rays due to the destruction of the ozone layer due to environmental pollution. As the aging population increases, the number of patients continues to increase worldwide.
한편, 많은 피부암 환자들이 처음 피부에 암이 발생했을 때 단순히 피부염 또는 점이나 종기로 간과하기 때문에 병원을 늦게 방문하여 조기 발견이 어려우므로, 병의 완치가 어렵게 되고 가끔 생명을 잃는 경우가 있다. 피부암 중 흔하고 많은 비중을 차지하는 피부암으로는 기저(基底)세포 암종(Basal cell carcinoma, BCC)으로 약 80%에 달하며, 그밖에도 약 16%에 달하는 편평상피(扁平上皮)세포 암종(squamous cell carcinoma, SCC), 그리고 약 4% 해당하는 흑색종(melanoma)이 있다. 기저세포암종(BCC)과 편평상피세포 암종(SCC)를 합쳐서 비흑색종성 암종(nonmelanoma skin cancer, NMSC)이라 일컫는다. 흑색종은 표피 내에 있는 멜라노사이트로부터 발생하는데, 대부분이 전이암이나 사망에 이르게 하는 암종이며, 2000년에는 47,000명이 새로운 흑색종으로 판명되었으며, 이 중 7,700명이 사망하였다고 보고된 바 있다(R. T. Greenlee et al. Cancer J. Clin., 50: 7-33, 2000). On the other hand, since many skin cancer patients are simply overlooked as dermatitis or spots or boils when the first skin cancer occurs, it is difficult to visit the hospital late and detect it early, making it difficult to cure the disease and sometimes even loses life. Among the skin cancers that are common and occupy a large proportion of skin cancers, basal cell carcinoma (BCC) accounts for about 80%, and squamous cell carcinoma (BCC), which accounts for about 16%. SCC), and melanoma, which corresponds to about 4%. Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are collectively referred to as nonmelanoma skin cancer (NMSC). Melanoma arises from melanocytes in the epidermis, most of which are metastatic cancers or carcinomas that lead to death.In 2000, 47,000 people were identified as new melanomas, of which 7,700 were reported to have died (RT Greenlee et al. al. Cancer J. Clin., 50: 7-33, 2000).
특히, 흑색종은 자외선의 만성적인 노출로 유발되기도 하지만, 극심한 선탠 등의 간헐적인 노출에 의해서 발생하는 것으로 예상하고 있다. 흑색종은 다른 피부암보다 예후가 나쁘기 때문에, 조기 발견이 되더라도 재발이 흔하며, 생명을 단축할 수 있다. 피부병변은 황갈색이나 검은색을 띄는 반점이나 결절로 나타나며, 보통 중년 이후에 태양 노출부에 의해 잘 발생한다. 때로는 손, 발가락, 특히 엄지손가락, 발가락의 말단에서도 생기며, 손발톱에 검은 색의 세로줄이 보일 수 있는데, 이때에는 흑색종을 의심하여 철저한 조사를 하여야 한다.In particular, melanoma may be caused by chronic exposure to ultraviolet rays, but is expected to occur due to intermittent exposure such as extreme sun tanning. Because melanoma has a worse prognosis than other skin cancers, recurrence is common even if detected early and can shorten life. Skin lesions appear as yellowish brown or black spots or nodules, and usually occur after middle age by sun exposure. Sometimes it occurs in the ends of the hands and toes, especially the thumb and toe, and black vertical lines may be seen on the nails. In this case, melanoma should be suspected and a thorough investigation should be conducted.
그러나, 아직까지는 피부암의 치료 약물들이 단지 피부암의 증상만을 완화하는 것이고, 근본적인 치료약의 개발이 이루어지지 못했을 뿐만 아니라, 많은 부작용이 알려져 있어, 현재까지는 피부암의 치료를 억제하는 치료제의 개발은 전무한 실정이다.However, so far, the treatment drugs for skin cancer only alleviate the symptoms of skin cancer, and the development of a fundamental treatment drug has not been achieved, and many side effects are known, so there is no development of a therapeutic agent to suppress the treatment of skin cancer until now. .
따라서, 보다 근본적이고 치료 또는 개선 효과가 우수할 뿐만 아니라, 부작용이 적은 새로운 피부암 치료제의 개발이 필요한 실정이다.Therefore, there is a need to develop a new treatment for skin cancer that is more fundamental and has excellent treatment or improvement effects, and has fewer side effects.
본 발명의 목적은 효모(yeast) 초음파 추출물을 유효성분으로 포함하는 피부암의 예방 또는 개선용 화장료 조성물을 제공하는 것이다.An object of the present invention is to provide a cosmetic composition for preventing or improving skin cancer comprising an ultrasonic yeast extract as an active ingredient.
본 발명의 또 다른 목적은 효모(yeast) 초음파 추출물을 유효성분으로 포함하는 피부암의 예방 또는 개선용 식품 조성물을 제공하는 것이다.Another object of the present invention is to provide a food composition for preventing or improving skin cancer comprising an ultrasonic yeast extract as an active ingredient.
본 발명의 또 다른 목적은 효모(yeast) 초음파 추출물을 유효성분으로 포함하는 피부암의 예방 또는 치료용 약학적 조성물을 제공하는 것이다.Another object of the present invention is to provide a pharmaceutical composition for preventing or treating skin cancer comprising an ultrasonic yeast extract as an active ingredient.
본 발명의 또 다른 목적은 효모(yeast) 초음파 추출물을 치료적 유효량을 개체에 투여하는 단계를 포함하는 피부암의 예방 또는 치료 방법을 제공하는 것이다. Another object of the present invention is to provide a method for preventing or treating skin cancer comprising administering a therapeutically effective amount of an ultrasonic yeast extract to an individual.
본 발명의 또 다른 목적은 피부암의 예방 또는 치료 효과를 가진 의약제제를 생산하기 위한 효모(yeast) 초음파 추출물의 사용을 제공하는 것이다. Another object of the present invention is to provide the use of an ultrasonic yeast (yeast) extract to produce a pharmaceutical formulation having a preventive or therapeutic effect of skin cancer.
본 발명의 또 다른 목적은 효모(yeast)에 수산화나트륨(NaOH) 수용액을 첨가하고, 초음파를 처리하는 단계를 포함하는 효모 초음파 추출물의 제조방법을 제공하는 것이다.Another object of the present invention is to provide a method for preparing an ultrasonic yeast extract comprising the step of adding an aqueous sodium hydroxide (NaOH) solution to yeast and treating ultrasonic waves.
상기 목적을 달성하기 위하여, 본 발명은 효모(yeast) 초음파 추출물을 유효성분으로 포함하는 피부암의 예방 또는 개선용 화장료 조성물을 제공한다. In order to achieve the above object, the present invention provides a cosmetic composition for preventing or improving skin cancer comprising an ultrasonic yeast (yeast) extract as an active ingredient.
또한, 본 발명은 효모(yeast) 초음파 추출물을 유효성분으로 포함하는 피부암의 예방 또는 개선용 식품 조성물을 제공한다. In addition, the present invention provides a food composition for preventing or improving skin cancer comprising an ultrasonic yeast extract as an active ingredient.
또한, 본 발명은 효모(yeast) 초음파 추출물을 유효성분으로 포함하는 피부암의 예방 또는 치료용 약학적 조성물을 제공한다. In addition, the present invention provides a pharmaceutical composition for preventing or treating skin cancer comprising an ultrasonic yeast extract as an active ingredient.
또한, 본 발명은 효모(yeast) 초음파 추출물을 치료적 유효량을 개체에 투여하는 단계를 포함하는 피부암의 예방 또는 치료 방법을 제공한다. In addition, the present invention provides a method for preventing or treating skin cancer comprising administering a therapeutically effective amount of an ultrasonic yeast extract to an individual.
또한, 본 발명은 피부암의 예방 또는 치료 효과를 가진 의약제제를 생산하기 위한 효모(yeast) 초음파 추출물의 사용을 제공한다. In addition, the present invention provides the use of an ultrasonic yeast (yeast) extract to produce a pharmaceutical formulation having a preventive or therapeutic effect of skin cancer.
또한, 본 발명은 효모(yeast)에 수산화나트륨(NaOH) 수용액을 첨가하고, 초음파를 처리하는 단계를 포함하는 효모 초음파 추출물의 제조방법을 제공한다. In addition, the present invention provides a method for preparing an ultrasonic yeast extract comprising the step of adding an aqueous sodium hydroxide (NaOH) solution to yeast and treating ultrasonic waves.
본 발명에 따른 효모 초음파 추출물은 피부암세포의 증식을 억제하는 활성이 우수하여 피부암의 예방, 개선 또는 치료를 위한 화장품, 기능성 식품 및 의약품의 제조에 유용하게 사용될 수 있다. The ultrasonic yeast extract according to the present invention has excellent activity of inhibiting the proliferation of skin cancer cells, and thus can be usefully used in the manufacture of cosmetics, functional foods and pharmaceuticals for the prevention, improvement or treatment of skin cancer.
도 1은 각 추출 조건에 따라 제조된 효모 초음파 추출물의 피부암 세포주에 대한 세포 증식 억제능을 분석한 결과이다.1 is a result of analyzing the cell proliferation inhibitory ability of the yeast ultrasonic extract prepared according to each extraction condition for skin cancer cell lines.
도 2는 각 추출 조건에 따라 제조된 효모 초음파 추출물에 대한 c-myc 및 cyclin D1의 단백질 발현 정도를 웨스턴블럿으로 분석한 결과이다. 2 is a result of Western blot analysis of the protein expression levels of c-myc and cyclin D1 for the ultrasonic yeast extract prepared according to each extraction condition.
도 3은 마우스에 B16F10 흑색종 세포주를 주입하여 종양을 형성시킨 후, 효모 초음파 추출물을 복강투여하고, 0, 2, 4 및 6일 후에 마우스에 형성된 종양을 나타낸 결과이다 (n=2). 3 is a result of tumor formation in mice by injecting B16F10 melanoma cell line into mice, followed by intraperitoneal administration of yeast ultrasound extract, and tumors formed in mice after 0, 2, 4 and 6 days (n=2).
도 4는 마우스에 B16F10 흑색종 세포주를 주입하여 종양을 형성시킨 후, 효모 초음파 추출물을 복강투여하고, 0, 2, 4 및 6일 후에 마우스에 형성된 종양크기를 측정한 결과이다 (n=2). 4 is a result of measuring tumor size in mice after injection of B16F10 melanoma cell line into mice to form a tumor, followed by intraperitoneal administration of an ultrasonic yeast extract, and after 0, 2, 4 and 6 days (n=2) .
도 5는 마우스에 B16F10 흑색종 세포주를 주입하여 종양을 형성시킨 후, 효모 초음파 추출물을 복강투여하고, 6일 후에 마우스의 종양조직 내 Cyclin D1 단백질의 발현 변화를 웨스턴블럿으로 측정한 결과이다 (n=3).5 is a result of measuring the change in expression of Cyclin D1 protein in the tumor tissue of the mouse after 6 days after intraperitoneal administration of the yeast ultrasound extract after injecting the B16F10 melanoma cell line into a mouse to form a tumor (n =3).
본 발명은 효모(yeast) 초음파 추출물을 유효성분으로 포함하는 피부암의 예방, 개선 또는 치료용 조성물을 제공한다. The present invention provides a composition for preventing, improving or treating skin cancer comprising an ultrasonic yeast extract as an active ingredient.
상기에서, 효모는 사카로미세스 세레비지에(Saccharomyces cerevisiae)인 것일 수 있다. In the above, the yeast may be Saccharomyces cerevisiae .
상기에서, 피부암은 흑색종(malignant melanoma), 유두종(papilloma), 암종(carcinoma), 편평세포암종(squamous cell carcinoma), 기저세포암종(basal cell carcinoma) 및 방추세포암종(spindle cell carcinoma)으로 이루어진 군에서 선택되는 것일 수 있으나, 이에 한정되는 것은 아니다. In the above, the skin cancer is composed of melanoma, papilloma, carcinoma, squamous cell carcinoma, basal cell carcinoma, and spindle cell carcinoma. It may be selected from the group, but is not limited thereto.
또한, 본 발명은 피부암세포의 증식을 효과적으로 저해할 수 있는 활성을 가진 효모 초음파 추출물의 제조방법을 제공한다. In addition, the present invention provides a method for producing an ultrasonic yeast extract having an activity capable of effectively inhibiting the proliferation of skin cancer cells.
상기 효모 초음파 추출물은 효모에 초음파를 처리하여 제조된 것이다. The yeast ultrasonic extract is prepared by treating yeast with ultrasonic waves.
본 발명에서는 수산화나트륨(NaOH) 수용액 처리와 초음파 처리를 함께 수행하여 얻은 효모의 초음파 추출물이 피부암 억제 활성이 우수함을 확인하였으며, 특히 0.1M 내지 0.2M의 수산화나트륨(NaOH) 수용액을 첨가하고 85℃ 내지 95℃에서 1.5시간 내지 2.5시간 동안 초음파를 처리하여 수득한 추출물이 가장 우수한 피부암 억제 활성이 있음을 확인하였다.In the present invention, it was confirmed that the ultrasonic extract of yeast obtained by performing the treatment of aqueous sodium hydroxide (NaOH) and ultrasonic treatment together has excellent skin cancer inhibitory activity. In particular, 0.1M to 0.2M aqueous sodium hydroxide (NaOH) solution was added and It was confirmed that the extract obtained by ultrasonic treatment at 95° C. for 1.5 to 2.5 hours has the best skin cancer inhibitory activity.
따라서, 본 발명은 피부암 억제 활성이 가지는 효모 초음파 추출물의 제조방법을 제공할 수 있으며, 바람직하게 상기 방법은 효모에 0.1M 내지 0.2M의 수산화나트륨(NaOH) 수용액을 첨가하고, 85℃ 내지 95℃에서 1.5시간 내지 2.5시간 동안 초음파를 처리하는 단계를 포함할 수 있다.Accordingly, the present invention can provide a method for preparing an ultrasonic yeast extract having skin cancer inhibitory activity, and preferably, the method comprises adding 0.1M to 0.2M sodium hydroxide (NaOH) aqueous solution to the yeast, and 85°C to 95°C It may include the step of ultrasonic treatment for 1.5 hours to 2.5 hours.
더욱 바람직하게는, 효모에 0.2M의 수산화나트륨(NaOH) 수용액을 첨가하고 90℃ 에서 2시간 동안 초음파를 처리하여 피부암 억제 활성이 우수한 효모 초음파 추출물을 수득할 수 있다.More preferably, 0.2M sodium hydroxide (NaOH) aqueous solution is added to the yeast and ultrasonicated at 90° C. for 2 hours to obtain an ultrasonic yeast extract having excellent skin cancer inhibitory activity.
본 발명의 방법에 있어서, 만일 수산화나트륨(NaOH)의 농도를 0.1M 미만으로 사용하게 되면 효모로부터 피부암 억제 활성을 갖는 생리활성 물질을 함유한 추출물의 추출이 미비한 문제가 있고, 반면 0.2M을 초과하여 사용하게 되면 높은 염기성 용액의 성질로 인해 추출물에 함유된 생리활성 물질의 변형을 초래할 수 있고 활성을 소실할 수 있는 문제점이 있다. 따라서, 수산화나트륨(NaOH)의 농도는 0.1M 내지 0.2M의 범위로 사용해야 하며, 가장 바람직하게는 0.2M 농도로 사용할 수 있다. In the method of the present invention, if the concentration of sodium hydroxide (NaOH) is less than 0.1M, there is a problem that extraction of an extract containing a physiologically active substance having skin cancer inhibitory activity from yeast is insufficient, whereas it exceeds 0.2M. When used, there is a problem in that the physiologically active substance contained in the extract may be modified and the activity may be lost due to the nature of the highly basic solution. Therefore, the concentration of sodium hydroxide (NaOH) should be used in the range of 0.1M to 0.2M, and most preferably, the concentration of 0.2M can be used.
또한, 상기 본 발명의 초음파 추출 시 추출 온도를 85℃ 미만에서 수행하게 되면 본 발명의 일실시예에서도 확인한 바와 같이, 효모 초음파 추출물의 피부암 억제 활성이 미비한 문제가 있고, 95℃를 초과한 온도에서 수행하게 되면 활성 성분의 파괴 또는 변성이 유발될 수 있어, 이 역시 피부암 억제 활성의 감소를 유발할 수 있다.In addition, when the extraction temperature is performed at less than 85°C during the ultrasonic extraction of the present invention, as confirmed in an embodiment of the present invention, there is a problem that the skin cancer inhibiting activity of the ultrasonic yeast extract is insufficient, and at a temperature exceeding 95°C If performed, the active ingredient may be destroyed or denatured, which may also cause a decrease in skin cancer inhibitory activity.
또한, 본 발명의 초음파 추출 시, 추출 시간은 1.5시간 내지 2.5시간에서 수행할 수 있다.In addition, in the ultrasonic extraction of the present invention, the extraction time may be performed in 1.5 hours to 2.5 hours.
1.5시간 미만으로 초음파 처리를 수행하게 되면, 효모로부터 피부암 억제 활성을 갖는 유용 추출물의 추출이 미비해 질 수 있고, 2.5시간을 초과하여 처리할 경우에도 효모 초음파 추출물의 피부암 억제 활성이 감소되는 문제가 있다.If the ultrasonic treatment is performed for less than 1.5 hours, extraction of useful extracts having skin cancer inhibitory activity from yeast may be insufficient, and even if the treatment exceeds 2.5 hours, there is a problem that the skin cancer inhibitory activity of the yeast ultrasonic extract is reduced. .
그러므로, 효모로부터 피부암의 억제 활성이 가장 우수한 추출물을 수득하기 위해서는, 반드시 0.1M 내지 0.2M의 수산화나트륨(NaOH) 수용액의 사용, 85℃ 내지 95℃의 온도, 1.5시간 내지 2.5시간 동안의 초음파 처리 조건 하에서 수행하여야 한다.Therefore, in order to obtain an extract with the best skin cancer inhibitory activity from yeast, be sure to use 0.1M to 0.2M sodium hydroxide (NaOH) aqueous solution, at a temperature of 85°C to 95°C, sonication for 1.5 to 2.5 hours. Must be performed under conditions.
또한, 본 발명의 방법으로 수득한 효모 초음파 추출물은 피부암에 대한 항암 활성이 우수한 특징이 있다.In addition, the ultrasonic yeast extract obtained by the method of the present invention has excellent anticancer activity against skin cancer.
특히, 상기 본 발명에 따른 조건으로 수득한 효모 초음파 추출물은 다른 종류의 암에 비해 피부암에 대한 항암 활성이 월등히 우수하다. In particular, the ultrasonic yeast extract obtained under the conditions according to the present invention has superior anticancer activity against skin cancer compared to other types of cancer.
본 발명의 일 실시예에서는, 각기 다른 조건으로 수득한 효모 초음파 추출물을 피부암의 일종인 흑색종 세포주에 처리한 후, 흑색종 세포주의 세포증식 억제능을 분석하였는데, 0.2M 수산화나트륨(NaOH) 수용액을 사용하여 90℃에서 2시간 동안 초음파를 처리하여 수득한 추출물이 월등히 우수한 세포 증식 억제능을 나타내었다.In one embodiment of the present invention, after treating the ultrasonic yeast extract obtained under different conditions to a melanoma cell line, which is a kind of skin cancer, the ability to inhibit cell proliferation of the melanoma cell line was analyzed, and 0.2M sodium hydroxide (NaOH) aqueous solution was used. The extract obtained by ultrasonic treatment at 90° C. for 2 hours showed remarkably excellent cell proliferation inhibitory ability.
이러한 효과는 동일 조건에서 1시간 또는 3시간 동안 초음파를 처리하여 수득한 추출물에 비해서도 우수한 효과임을 확인할 수 있었다.This effect was confirmed to be an excellent effect compared to the extract obtained by ultrasonic treatment for 1 hour or 3 hours under the same conditions.
나아가, 본 발명자들은 본 발명의 효모 초음파 추출물에 대한 피부암 억제 활성이 어떠한 기전을 통해 일어나는 것인지 확인하기 위해, 본 발명의 효모 초음파 추출물 처리에 따른 세포내 c-myc 및 cyclin D1의 단백질 발현 변화를 분석하였다.Further, the present inventors analyzed the protein expression changes of c-myc and cyclin D1 in cells according to the treatment of the ultrasonic yeast extract of the present invention in order to determine through which mechanism the skin cancer inhibitory activity of the ultrasonic yeast extract of the present invention occurs. I did.
그 결과, 본 발명의 효모 초음파 추출물을 처리한 군에서 c-myc의 발현은 추출물을 처리하지 않은 군과 발현수준의 변화를 보이지는 않았으나, cyclin D1 단백질의 발현수준은 현저하게 감소되는 것으로 나타났다.As a result, the expression of c-myc in the group treated with the ultrasonic yeast extract of the present invention did not show any change in the expression level compared to the group not treated with the extract, but the expression level of the cyclin D1 protein was significantly decreased.
따라서, 본 발명의 효모 초음파 추출물은 피부암 세포의 세포주기에 관여하는 cyclin D1의 발현 및 활성 억제를 통해 암세포의 증식을 저해하여 피부암에 대한 항암 활성을 나타낸다는 것을 알 수 있었다.Therefore, it was found that the ultrasonic yeast extract of the present invention inhibits the proliferation of cancer cells through inhibition of the expression and activity of cyclin D1 involved in the cell cycle of skin cancer cells, thereby exhibiting anticancer activity against skin cancer.
그러므로, 본 발명의 방법으로 제조된 효모 초음파 추출물은 피부암의 예방, 개선 또는 치료를 위한 화장품, 건강기능식품 및 의약품의 제조에 유용하게 사용할 수 있다.Therefore, the ultrasonic yeast extract prepared by the method of the present invention can be usefully used in the manufacture of cosmetics, health functional foods and pharmaceuticals for the prevention, improvement or treatment of skin cancer.
이에 본 발명은 효모 초음파 추출물을 유효성분으로 포함하는 피부암의 예방 또는 개선용 화장료 조성물을 제공한다. Accordingly, the present invention provides a cosmetic composition for preventing or improving skin cancer comprising an ultrasonic yeast extract as an active ingredient.
본 발명의 화장료 조성물에 있어서, 상기 조성물은 화장품 분야에서 통상적으로 사용되는 기제, 보조제 및 첨가제를 사용하여 액체 또는 고체 형태로 제조될 수 있다. 액체 또는 고체 형태의 화장품으로는, 예를 들면 이에 한정되지는 않으나 화장수, 크림제, 로션제, 입욕제 등의 형태를 포함할 수 있다.In the cosmetic composition of the present invention, the composition may be prepared in a liquid or solid form using bases, auxiliary agents and additives commonly used in the cosmetic field. Cosmetics in a liquid or solid form may include, for example, but not limited to, a form such as a lotion, cream, lotion, and bath agent.
화장품 분야에서 통상적으로 사용되는 기제, 보조제 및 첨가제는 특별히 제한되지 않으며, 예를 들면 물, 알코올, 프로필렌글리콜, 스테아르산, 글리세롤, 세틸알코올, 유동 파라핀 등이 있다.Bases, adjuvants and additives commonly used in the cosmetic field are not particularly limited, and examples include water, alcohol, propylene glycol, stearic acid, glycerol, cetyl alcohol, liquid paraffin, and the like.
본 발명의 조성물이 화장료 조성물로 제조되는 경우, 본 발명의 조성물은 효모 초음파 추출물뿐만 아니라, 화장료 조성물에 통상적으로 이용되는 성분들을 포함할 수 있으며, 예컨대 항산화제, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제, 그리고 담체를 포함할 수 있다.When the composition of the present invention is prepared as a cosmetic composition, the composition of the present invention may include not only an ultrasonic yeast extract, but also ingredients commonly used in cosmetic compositions, such as antioxidants, stabilizers, solubilizers, vitamins, pigments And conventional adjuvants such as fragrances, and carriers.
본 발명의 화장료 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클린싱, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이 등으로 제형화될 수 있으나, 이에 한정되는 것은 아니다. 보다 상세하게는, 유연 화장수, 영양 화장수, 영양 크림, 마사지 크림, 에센스, 아이 크림, 클렌징 크림, 클렌징 포옴, 클렌징 워터, 팩, 스프레이 또는 파우더의 제형으로 제조될 수 있다. The cosmetic composition of the present invention may be prepared in any formulation conventionally prepared in the art, for example, solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleaning, It may be formulated as an oil, powder foundation, emulsion foundation, wax foundation, and spray, but is not limited thereto. In more detail, it may be prepared in the form of a flexible lotion, nutritional lotion, nutritional cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray or powder.
또한, 본 발명의 피부암 예방 또는 개선용 화장료 조성물에 있어, 본 발명의 유효성분의 함량은 조성물 총 중량 대비 0.0001 내지 20 중량%인 것이 바람직하다. 유효성분의 함량이 0.0001 중량% 미만인 경우에는 본래 목적하는 피부암 개선 또는 예방 효과를 충분하게 달성할 수 없어 바람직하지 못하며, 유효성분의 함량이 20 중량%를 초과하는 경우에는 조성물의 안정성에 문제를 발생시킬 수 있고, 이로 인해 조성물의 외관에 문제를 일으킬 우려가 있다. In addition, in the cosmetic composition for preventing or improving skin cancer of the present invention, the content of the active ingredient of the present invention is preferably 0.0001 to 20% by weight based on the total weight of the composition. If the content of the active ingredient is less than 0.0001% by weight, it is not preferable because the intended skin cancer improvement or prevention effect cannot be sufficiently achieved.If the content of the active ingredient exceeds 20% by weight, a problem occurs in the stability of the composition. Can be made, and there is a risk of causing a problem in the appearance of the composition.
나아가, 본 발명은 효모 초음파 추출물을 유효성분으로 포함하는 피부암의 예방 또는 개선용 식품 조성물을 제공한다. Furthermore, the present invention provides a food composition for preventing or improving skin cancer comprising an ultrasonic yeast extract as an active ingredient.
본 발명의 식품 조성물은 기능성 식품(functional food), 영양 보조제(nutritional supplement), 건강식품(health food) 및 식품 첨가제(food additives) 등의 모든 형태를 포함한다. 상기 유형의 식품 조성물은 당 업계에 공지된 통상적인 방법에 따라 다양한 형태로 제조할 수 있다.The food composition of the present invention includes all forms such as functional food, nutritional supplement, health food and food additives. Food compositions of this type can be prepared in various forms according to conventional methods known in the art.
예를 들면, 건강식품으로는 본 발명의 효모 초음파 추출물을 이용하여 차, 쥬스 및 드링크의 형태로 제조하여 음용하도록 하거나, 과립화, 캡슐화 및 분말화 하여 섭취할 수 있다. 또한, 피부암 예방 또는 개선 효과가 있다고 알려진 공지의 물질 또는 활성 성분과 함께 혼합하여 조성물의 형태로 제조할 수 있다.For example, as a health food, it can be prepared in the form of tea, juice, and drinks using the ultrasonic yeast extract of the present invention and consumed, or granulated, encapsulated, and powdered. In addition, it may be prepared in the form of a composition by mixing with known substances or active ingredients known to have an effect of preventing or improving skin cancer.
또한, 기능성 식품으로는 음료(알코올성 음료 포함), 과실 및 그의 가공식품(예: 과일통조림, 병조림, 잼, 마아말레이드 등), 어류, 육류 및 그 가공식품(예: 햄, 소시지콘비이프 등), 빵류 및 면류(예: 우동, 메밀국수, 라면, 스파게티, 마카로니 등), 과즙, 각종 드링크, 쿠키, 엿, 유제품(예: 버터, 치이즈 등), 식용식물유지, 마아가린, 식물성 단백질, 레토르트 식품, 냉동식품, 각종 조미료(예: 된장, 간장, 소스 등) 등에 본 발명의 유효성분을 첨가하여 제조할 수 있다.In addition, functional foods include beverages (including alcoholic beverages), fruits and processed foods thereof (eg, canned fruit, canned food, jam, marmalade, etc.), fish, meat and processed foods thereof (eg, ham, sausage corn beef, etc.) ), breads and noodles (e.g. udon, soba, ramen, spaghetti, macaroni, etc.), fruit juice, various drinks, cookies, syrup, dairy products (e.g. butter, cheese, etc.), edible vegetable oil, margarine, vegetable protein, It can be prepared by adding the active ingredient of the present invention to retort foods, frozen foods, various seasonings (eg, miso, soy sauce, sauce, etc.).
본 발명의 식품 조성물 중 상기 본 발명의 유효성분에 대한 바람직한 함유량으로는 이에 한정되지 않지만 바람직하게는 최종적으로 제조된 식품 중 고형물 함량 0.01 내지 50 중량%로 포함될 수 있다. 또한 식품 첨가제의 형태로 사용하기 위해서는 본 발명의 조성물을 분말 또는 농축액 형태로 제조하여 사용할 수 있다. The preferred content of the active ingredient of the present invention in the food composition of the present invention is not limited thereto, but may preferably be contained in a solid content of 0.01 to 50% by weight in the finally prepared food. In addition, for use in the form of a food additive, the composition of the present invention may be prepared and used in the form of a powder or a concentrate.
또한, 본 발명은 효모 초음파 추출물을 유효성분으로 포함하는 피부암의 예방 또는 치료용 약학적 조성물을 제공한다. In addition, the present invention provides a pharmaceutical composition for preventing or treating skin cancer comprising an ultrasonic yeast extract as an active ingredient.
상기 약학적 조성물은 정제, 캡슐제, 환제, 과립제, 산제, 엑기스제, 현탁액, 에멀젼, 시럽, 에어로졸의 경구형, 제형, 연고, 도포제, 수액제의 외용제형 또는 정맥, 근육, 피하, 뇌혈관내 투여를 위한 멸균 주사용액 또는 좌제 형태로 제조될 수 있다. The pharmaceutical composition is a tablet, capsule, pill, granule, powder, extract, suspension, emulsion, syrup, aerosol oral form, formulation, ointment, coating, or intravenous, intramuscular, subcutaneous, cerebrovascular It can be prepared in the form of a sterile injectable solution or suppository for administration.
본 발명의 약학적 조성물의 약제학적 투여 형태는 단독으로 또는 기타 치료학적으로 유용한 약학적 활성물질을 함유할 수 있으며, 약제학적 조성물의 제조에 통상적으로 허용되는 적절한 담체와 함께 배합하여 통상적인 방법에 의해 다양한 형태로 제형화할 수 있다.The pharmaceutical dosage form of the pharmaceutical composition of the present invention, alone or may contain other therapeutically useful pharmaceutically active substances, can be combined with an appropriate carrier that is generally acceptable for the manufacture of pharmaceutical compositions to be used in a conventional method. It can be formulated in various forms.
본 발명의 약학적 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 덱스트로즈, 락토즈, 수크로스, 전분, 솔비톨, 만니톨, 자일리톨, 아카시아 고무, 칼슘 실리케이트, 칼슘 포스페이트, 알기네이트, 젤라틴, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 물, 프로필히드록시벤조에이트, 광물유, 메틸히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 등이 있다. 제제화할 경우에는 보통 사용하는 결합제, 붕해제, 충진제, 증량제, 계면활성제, 습윤제 등의 희석제 또는 부형제를 사용하여 조제될 수 있다.Carriers, excipients and diluents that may be included in the pharmaceutical composition of the present invention include dextrose, lactose, sucrose, starch, sorbitol, mannitol, xylitol, gum acacia, calcium silicate, calcium phosphate, alginate, gelatin, cellulose , Methyl cellulose, microcrystalline cellulose, water, propylhydroxybenzoate, mineral oil, methylhydroxybenzoate, talc, magnesium stearate, and the like. In the case of formulation, it can be prepared by using diluents or excipients such as commonly used binders, disintegrants, fillers, extenders, surfactants, and wetting agents.
경구투여를 위한 고형제제에는 정제, 캡슐제, 환제, 과립제, 산제 등이 포함되며 이러한 고형제제는 상기 본 발명의 유효성분에 적어도 하나 이상의 부형제, 예를 들면 전분, 수크로스 또는 락토오스, 젤라틴 등을 섞어서 조제된다. Solid preparations for oral administration include tablets, capsules, pills, granules, powders, and the like, and these solid preparations contain at least one excipient, such as starch, sucrose or lactose, gelatin, etc. in the active ingredient of the present invention. It is prepared by mixing.
또한, 단순한 부형제 이외에 탈크, 마그네슘 스테아레이트 등의 윤활제도 사용될 수 있다. 경구투여를 위한 액상제제로는 현탁제, 내용액제, 유제, 시럽제 등이 있는데 빈번히 사용되는 단순 희석제인 물, 액체파라핀 외에 여러 가지 부형제, 예를 들면 방향제, 보존제, 습윤제, 감미제 등이 포함될 수 있다.In addition, in addition to simple excipients, lubricants such as talc and magnesium stearate may be used. Liquid preparations for oral administration include suspensions, solvents, emulsions, syrups, etc., but may include water and liquid paraffin, which are frequently used simple diluents, as well as various excipients, such as fragrances, preservatives, humectants, and sweeteners. .
비경구 투여를 위한 용액 또는 현탁액 형태의 주사제는 피하, 정맥내, 근육내, 또는 복강내로 투여될 수 있다.Injections in the form of solutions or suspensions for parenteral administration may be administered subcutaneously, intravenously, intramuscularly, or intraperitoneally.
일반적으로 주사가 가능한 용액 또는 현탁액은 물, 염수, 수성 텍스트로스 및 관련 당 용액제, 비휘발성 오일, 에탄올, 글리세린, 폴리에틸렌글리콜, 프로필렌글리콜과 같은 글리콜류 등의 약제학적으로 허용되는 액상 담체 중에 유효량이 본 발명의 유효성분을 균질하게 혼합시켜 제조할 수 있다. 이외에도 필요에 따라 가용화제, 항세균제, 킬레이트제, 완충제, 보존제와 같은 보조제를 포함시킬 수 있다.In general, injectable solutions or suspensions are in an effective amount in a pharmaceutically acceptable liquid carrier such as water, saline, aqueous textrose and related sugar solutions, non-volatile oils, ethanol, glycerin, polyethylene glycol, and glycols such as propylene glycol. It can be prepared by homogeneously mixing the active ingredients of the present invention. In addition, auxiliary agents such as solubilizing agents, antibacterial agents, chelating agents, buffering agents, and preservatives may be included as necessary.
도포제는 통상적인 제조방법에 따라 크림제, 연고제, 현탁제, 에멀젼 등 다양한 형태로 용이하게 제조할 수 있다. 연고 또는 크림형으로 제조할 경우, 일반적인 수중유형 또는 유중수형의 베이스에 본 발명의 유효성분을 함유시키고, 향료, 킬레이트제, 색소, 산화방지제, 방부제 등을 필요에 따라 사용할 수 있고 물성 개선을 목적으로 비타민, 단백질, 미네랄 등을 병용할 수 있다.The coating agent can be easily prepared in various forms such as cream, ointment, suspension, and emulsion according to a conventional manufacturing method. When prepared as an ointment or cream type, the active ingredient of the present invention is contained in a general water-in-water type or water-in-oil type base, and flavors, chelating agents, coloring agents, antioxidants, preservatives, etc. can be used as needed, and the purpose of improving physical properties Vitamins, proteins, minerals, etc. can be used in combination.
본 발명에서, 유효성분의 투여량은 환자의 체중, 질병의 중증도, 약물제형, 건강상태, 투여경로 및 투여기간에 따라 변화될 수 있다. 바람직한 효과를 위해서는 1일 0.001 내지 10g/kg, 바람직하게는 0.01 내지 0.1g/kg으로 투여하는 것이 좋고, 이에 제한하는 것은 아니다. 투여는 1일 1회 또는 수회에 나누어 투여할 수 있다.In the present invention, the dosage of the active ingredient may be changed according to the weight of the patient, the severity of the disease, the drug formulation, the state of health, the route of administration, and the administration period. For a desirable effect, it is good to administer 0.001 to 10 g/kg per day, preferably 0.01 to 0.1 g/kg, but is not limited thereto. Administration can be administered once a day or divided into several times.
또한, 본 발명은 효모(yeast) 초음파 추출물을 치료적 유효량을 개체에 투여하는 단계를 포함하는 피부암의 예방 또는 치료 방법을 제공한다. In addition, the present invention provides a method for preventing or treating skin cancer comprising administering a therapeutically effective amount of an ultrasonic yeast extract to an individual.
상기 치료적 유효량은 달성하고자 하는 반응의 종류와 정도, 경우에 따라 다른 제제가 사용되는지의 여부를 비롯한 구체적 조성물, 개체의 연령, 체중, 일반건강 상태, 성별 및 식이, 투여 시간, 투여 경로 및 조성물의 분비율, 치료기간, 구체적 조성물과 함께 사용되거나 동시 사용되는 약물을 비롯한 다양한 인자와 의약 분야에 잘 알려진 유사 인자에 따라 다르게 적용하는 것이 바람직하다. 따라서 본 발명의 목적에 적합한 조성물의 유효량은 전술한 사항을 고려하여 결정하는 것이 바람직하다.The therapeutically effective amount is a specific composition including the type and degree of the reaction to be achieved, whether or not other agents are used in some cases, the individual's age, weight, general health status, sex and diet, administration time, administration route and composition. It is preferable to apply differently depending on various factors including the secretion rate of the drug, the treatment period, drugs used with or concurrently with the specific composition, and similar factors well known in the medical field. Therefore, it is preferable to determine an effective amount of a composition suitable for the purposes of the present invention in consideration of the foregoing.
상기 개체는 임의의 포유동물에 적용가능하며, 상기 포유동물은 인간 및 영장류뿐만 아니라, 소, 돼지, 양, 말, 개 및 고양이 등의 가축을 포함한다.The individual is applicable to any mammal, and the mammal includes humans and primates, as well as livestock such as cattle, pigs, sheep, horses, dogs and cats.
또한, 본 발명은 피부암의 예방 또는 치료 효과를 가진 의약제제를 생산하기 위한 효모(yeast) 초음파 추출물의 사용을 제공한다. In addition, the present invention provides the use of an ultrasonic yeast (yeast) extract to produce a pharmaceutical formulation having a preventive or therapeutic effect of skin cancer.
이하, 본 발명을 실시예를 통하여 더욱 상세히 설명하기로 한다. 이들 실시예는 본 발명을 보다 구체적으로 설명하기 위한 것으로서, 본 발명의 범위가 이들 실시예에 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail through examples. These examples are for explaining the present invention more specifically, and the scope of the present invention is not limited to these examples.
실시예 1. 효모 초음파 추출물의 제조Example 1. Preparation of ultrasonic yeast extract
본 발명자들은 피부암 억제 활성을 가진 효모 추출물을 제조하기 위하여, 다음과 같은 추출 조건을 달리하여 효모 초음파 추출물을 제조하였다.In order to prepare a yeast extract having skin cancer inhibitory activity, the present inventors prepared an ultrasonic yeast extract by varying the following extraction conditions.
먼저, NaOH가 각 농도별 (0.15 및 0.2M)로 용해된 수용액을 분말 형태의 효모(Saccharomyces cerevisiae;(주)셀텍에서 구입)에 첨가하고(효모양 기준 10배량(w/v)으로 NaOH 수용액 첨가), 시간별(1hr, 3hr, 5hr)로 초음파 처리하여 초음파 추출물을 제조하였는데, 이때 상기 초음파 처리 조건은 20 kHz, 80% amplitude, 750 W, pulse 20 s on/10 s off 하에서 수행하였으며, 온도는 각각 90℃, 70℃ 및 50℃로 달리하여 추출하였다. First, an aqueous solution in which NaOH was dissolved in each concentration (0.15 and 0.2M) was added to yeast in powder form (Saccharomyces cerevisiae; purchased from Celltech Co., Ltd.) (10 times the amount of yeast (w/v)). Addition) and hourly (1hr, 3hr, 5hr) ultrasonic treatment to prepare an ultrasonic extract, wherein the ultrasonic treatment conditions were 20 kHz, 80% amplitude, 750 W, pulse 20 s on/10 s off, and temperature Was extracted by differently at 90°C, 70°C and 50°C, respectively.
이후, 각 수득한 모든 추출물은 HCl로 중화한 후 탈염하여 동결건조한 다음, 하기 실험을 수행하였다. 대조군은 초음파 처리 없이 알칼리 용액만을 이용하여 수득한 효모 추출물을 사용하였다.Thereafter, all the extracts obtained were neutralized with HCl, desalted, lyophilized, and then the following experiment was performed. As a control, a yeast extract obtained using only an alkaline solution without sonication was used.
실시예 2. 효모 초음파 추출물의 피부암 세포주에 대한 증식 억제능 분석Example 2. Analysis of the ability of ultrasonic yeast extract to inhibit proliferation of skin cancer cell lines
상기 실시예 1에서 수득한 각 효모 초음파 추출물에 대한 피부암 억제 활성 여부를 확인하기 위하여, B16F10 흑색종 세포주에 각 효모 초음파 추출물을 처리한 후, 세포증식 정도를 분석하였다. 세포증식 분석에 사용된 각 시료는 하기 표 1에 나타내었다. In order to confirm the skin cancer inhibitory activity of each yeast ultrasonic extract obtained in Example 1, the B16F10 melanoma cell line was treated with each yeast ultrasonic extract, and then the degree of cell proliferation was analyzed. Each sample used in the cell proliferation analysis is shown in Table 1 below.
B16F10 흑색종 세포주의 세포증식 분석은 다음과 같은 방법으로 수행하였다. 간단히, B16F10 흑색종 세포주는 96 웰 플레이트에서 하나의 웰당 4 x 103 세포로 분주하였고, 세포 분주 3시간 후 각 초음파 추출물을 다양한 농도로 처리한 다음, 37℃, 5% CO2 조건 하에서 3일 동안 배양하였다. 3일 배양 후 Promega CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay (MTS) 시약을 이용하여 살아있는 세포를 발색하여 세포증식 정도를 측정하였다.Cell proliferation analysis of the B16F10 melanoma cell line was performed in the following manner. Briefly, the B16F10 melanoma cell line was dispensed at 4 x 10 3 cells per well in a 96 well plate, and each ultrasonic extract was treated at various concentrations 3 hours after the cell dispensing, and then for 3 days under conditions of 37°C and 5% CO 2 During incubation. After incubation for 3 days, live cells were colored using Promega CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay (MTS) reagent to measure the degree of cell proliferation.
그 결과, 초음파를 처리하여 수득한 효모 초음파 추출물(#2 ~ #13)은 초음파 처리 없이 알칼리 추출법으로 수득한 대조군(control, #1)에 비하여 흑색종 세포의 증식 억제 효과가 더 우수한 것으로 확인되었다 (도 1). 특히, 0.2M 농도의 NaOH 수용액에서 2시간 동안 90℃에서 초음파 처리하여 수득한 효모 초음파 추출물(#10, #11)은 다른 조건으로 수득한 추출물에 비하여 흑색종 세포주의 세포증식 억제 효과가 현저한 것으로 확인되었다 (도 1). As a result, it was confirmed that the yeast ultrasonic extract (#2 ~ #13) obtained by ultrasonic treatment had a better inhibitory effect on the proliferation of melanoma cells compared to the control (control, #1) obtained by the alkaline extraction method without ultrasonic treatment. (Fig. 1). In particular, the yeast ultrasonic extracts (#10, #11) obtained by ultrasonic treatment at 90°C for 2 hours in 0.2M aqueous NaOH solution have a remarkable effect of inhibiting cell proliferation of melanoma cell lines compared to extracts obtained under other conditions. Confirmed (Fig. 1).
한편, 상기 조건으로 수득한 본 발명의 효모 초음파 추출물은 0.2M 농도보다 낮은 농도인 0.15M NaOH 수용액을 사용하여 수득한 추출물 및 0.2M 보다 높은 농도인 0.5M NaOH 수용액을 사용하여 수득한 추출물에 비하여 피부암 세포주의 세포증식 억제 활성이 현저한 것으로 확인되었다. On the other hand, the ultrasonic yeast extract of the present invention obtained under the above conditions was compared to the extract obtained using a 0.15M NaOH aqueous solution having a concentration lower than 0.2M and an extract obtained using a 0.5M NaOH aqueous solution having a concentration higher than 0.2M. It was confirmed that the cell proliferation inhibitory activity of skin cancer cell lines was remarkable.
상기 결과로부터, 본 발명자들은 0.2M 농도의 NaOH 수용액, 2시간 동안 90℃의 온도에서 20 kHz, 80% amplitude, 750 W, pulse 20 s on/10 s off 조건으로 초음파 처리하여 수득한 추출물이 피부암에 대한 항암 활성에 현저한 효과가 있음을 확인하였다. From the above results, the present inventors found that the extract obtained by ultrasonic treatment under the conditions of 20 kHz, 80% amplitude, 750 W, pulse 20 s on/10 s off at a temperature of 90° C. for 2 hours in a 0.2M aqueous NaOH solution It was confirmed that there is a remarkable effect on anticancer activity against.
실시예 3. 효모 초음파 추출물에 대한 Cyclin D1 발현수준 분석Example 3. Analysis of Cyclin D1 Expression Level for Yeast Ultrasonic Extract
상기 실시예 2의 결과로부터, 효모 초음파 추출물이 피부암에 대한 항암 활성에 현저한 효과가 있음을 확인하였다. 이에 본 발명자들은 효모 초음파 추출물의 피부암 억제에 대한 세포 내 기전에 미치는 영향을 확인하기 위한 실험을 수행하였다. c-myc은 발암 유전자로 알려져 있고, Cyclin D1은 암세포에서 과발현되는 것으로 알려져 있다. 본 발명자들은 효모 초음파 추출물 처리 시, 흑색종 세포주에서 c-myc 및 Cyclin D1 단백질의 발현수준 변화를 웨스턴블럿을 통해 확인하였다.From the results of Example 2, it was confirmed that the ultrasonic yeast extract has a remarkable effect on anticancer activity against skin cancer. Accordingly, the present inventors conducted an experiment to confirm the effect of the ultrasonic yeast extract on the intracellular mechanism on the inhibition of skin cancer. c-myc is known to be an oncogene, and Cyclin D1 is known to be overexpressed in cancer cells. The present inventors confirmed changes in the expression levels of c-myc and Cyclin D1 proteins in melanoma cell lines through Western blot when the yeast ultrasonic extract was treated.
그 결과, 효모 초음파 추출물은 대조군에 비하여 Cyclin D1 단백질의 발현을 현저하게 억제하는 효과가 있음을 확인하였다 (도 2). 특히, 0.15M 및 0.2M 농도의 NaOH 수용액에서 2시간 동안 90℃에서 초음파 처리하여 수득한 추출물은 다른 조건으로 수득한 추출물(0.2M NaOH 수용액, 3시간, 70℃에서 초음파 처리; 또는 0.2M NaOH 수용액, 3시간, 50℃에서 초음파 처리)에 비하여 Cyclin D1 단백질의 발현을 현저하게 억제하는 효과가 있음을 확인하였다 (도 2). 다만, c-myc 의 발현에는 어떠한 영향을 미치지 않았다 (도 2). As a result, it was confirmed that the ultrasonic yeast extract has the effect of remarkably suppressing the expression of the Cyclin D1 protein compared to the control (FIG. 2). In particular, the extract obtained by sonicating at 90°C for 2 hours in an aqueous NaOH solution of 0.15M and 0.2M concentration was obtained under different conditions (0.2M NaOH aqueous solution, 3 hours, ultrasonic treatment at 70°C; or 0.2M NaOH) It was confirmed that there is an effect of remarkably suppressing the expression of Cyclin D1 protein compared to aqueous solution, 3 hours, sonication at 50°C) (Fig. 2). However, there was no effect on the expression of c-myc (Fig. 2).
상기 결과로부터, 본 발명자들은 효모 초음파 추출물이 Cyclin D1의 발현을 억제함으로써, 피부암 세포주의 세포증식 억제하고, 피부암에 대한 항암 활성에 현저한 효과가 있음을 확인하였다. From the above results, the present inventors confirmed that the ultrasonic yeast extract inhibits the expression of Cyclin D1, thereby inhibiting cell proliferation of skin cancer cell lines and has a remarkable effect on anticancer activity against skin cancer.
실시예 4. Example 4.
in vivoin vivo
에서 효모 초음파 추출물의 피부암에 대한 항암 활성 분석 Analysis of Anticancer Activity of Yeast Ultrasound Extract on Skin Cancer
본 발명자들은 효모 초음파 추출물이 피부암에 대한 항암 활성을 확인하기 위하여, 동물모델에서 효모 초음파 추출물을 처리하여 종양 크기 분석 및 종양조직 내 Cyclin D1 발현수준을 분석하는 실험을 수행하였다. 간단히, 6주령 BALB/c-nu 마우스가 실험에 사용되었고, 마우스는 구입 후 1주일 동안 적응시켰다. 이후, 각 마우스의 등쪽 피부조직에 B16F10 흑색종 세포주 (세포수: 5x105 개)를 주입하였다. 마우스의 등쪽 피부조직에 종양이 형성됨을 확인한 후, 효모 초음파 추출물 (500 mg/kg·body weight)을 2일에 1회씩 복강투여하였다. 효모 초음파 추출물의 투여 후 0, 2, 4 및 6일 후에 종양 크기를 분석하였고, 효모 초음파 추출물의 투여 후 6일 후에 종양조직 내 Cyclin D1 단백질의 발현 변화를 웨스턴블럿으로 측정하였다. In order to confirm the anticancer activity of the yeast ultrasonic extract against skin cancer, the present inventors performed an experiment to analyze the tumor size and the expression level of Cyclin D1 in the tumor tissue by treating the ultrasonic yeast extract in an animal model. Briefly, 6 week old BALB/c-nu mice were used in the experiment, and mice were acclimated for 1 week after purchase. Thereafter, the B16F10 melanoma cell line (cell number: 5 ×10 5 cells) was injected into the dorsal skin tissue of each mouse. After confirming that tumors were formed in the dorsal skin tissue of the mouse, the yeast ultrasound extract (500 mg/kg body weight) was administered intraperitoneally once every 2 days. Tumor size was analyzed 0, 2, 4 and 6 days after administration of the yeast ultrasound extract, and changes in the expression of Cyclin D1 protein in the tumor tissue were measured by Western blot 6 days after administration of the yeast ultrasound extract.
그 결과, 효모 초음파 추출물을 처리한 마우스에서는 추출물을 처리하지 않은 대조군에 비하여 종양크기가 현저하게 작아졌음을 확인하였다 (도 3). 특히, 효모 초음파 추출물을 6일 동안 처리한 마우스에서는 종양크기가 약 593 mm3 으로 확인되었고, 이는 추출물을 처리하지 않은 대조군(약 945 mm3)에 비하여 약 63% 정도로 종양크기가 줄어들었음을 확인하였다 (도 4). As a result, it was confirmed that in the mice treated with the yeast ultrasonic extract, the tumor size was significantly reduced compared to the control group not treated with the extract (FIG. 3). In particular, in mice treated with the yeast ultrasound extract for 6 days, the tumor size was confirmed to be about 593 mm 3 , which was confirmed that the tumor size was reduced by about 63% compared to the control group (about 945 mm 3 ) not treated with the extract. (Fig. 4).
또한, 효모 초음파 추출물을 처리한 마우스의 종양 조직에서는 Cyclin D1 단백질의 발현이 현저하게 감소되었음을 확인하였다 (도 5). In addition, it was confirmed that the expression of Cyclin D1 protein was significantly reduced in tumor tissues of mice treated with the yeast ultrasound extract (FIG. 5).
상기 결과로부터, 본 발명자들은 피부암 동물모델에서도 효모 초음파 추출물이 항암 활성에 현저한 효과가 있음을 확인하였다. From the above results, the present inventors confirmed that the ultrasonic yeast extract has a remarkable effect on anticancer activity even in an animal model of skin cancer.
Claims (10)
- 효모(yeast) 초음파 추출물을 유효성분으로 포함하는 피부암의 예방 또는 개선용 화장료 조성물.A cosmetic composition for preventing or improving skin cancer comprising an ultrasonic yeast extract as an active ingredient.
- 제 1 항에 있어서,The method of claim 1,상기 효모는 사카로미세스 세레비지에(Saccharomyces cerevisiae)인 것인 조성물. The yeast is a composition that is Saccharomyces cerevisiae ( Saccharomyces cerevisiae ).
- 제 1 항에 있어서,The method of claim 1,상기 효모 초음파 추출물은 효모에 초음파를 처리하여 제조된 것인 조성물. The yeast ultrasonic extract is a composition prepared by treating yeast with ultrasonic waves.
- 제 3 항에 있어서,The method of claim 3,상기 초음파는 효모에 0.1 M 내지 0.2 M의 수산화나트륨(NaOH) 수용액을 첨가하고, 85℃ 내지 95℃에서 1.5시간 내지 2.5시간 동안 수행되는 것인 조성물. The ultrasonic wave is a composition in which 0.1 M to 0.2 M sodium hydroxide (NaOH) aqueous solution is added to the yeast, and is performed at 85° C. to 95° C. for 1.5 to 2.5 hours.
- 제 1 항에 있어서, The method of claim 1,상기 피부암은 흑색종(malignant melanoma), 유두종(papilloma), 암종(carcinoma), 편평세포암종(squamous cell carcinoma), 기저세포암종(basal cell carcinoma) 및 방추세포암종(spindle cell carcinoma)으로 이루어진 군에서 선택되는 것인 조성물.The skin cancer is in the group consisting of malignant melanoma, papilloma, carcinoma, squamous cell carcinoma, basal cell carcinoma, and spindle cell carcinoma. The composition of which is selected.
- 효모(yeast) 초음파 추출물을 유효성분으로 포함하는 피부암의 예방 또는 개선용 식품 조성물.A food composition for preventing or improving skin cancer comprising an ultrasonic yeast extract as an active ingredient.
- 효모(yeast) 초음파 추출물을 유효성분으로 포함하는 피부암의 예방 또는 치료용 약학적 조성물.A pharmaceutical composition for the prevention or treatment of skin cancer comprising an ultrasonic yeast extract as an active ingredient.
- 효모(yeast)에 수산화나트륨(NaOH) 수용액을 첨가하고, 초음파를 처리하는 단계를 포함하는 효모 초음파 추출물의 제조방법.A method for producing an ultrasonic yeast extract comprising the step of adding an aqueous sodium hydroxide (NaOH) solution to yeast and performing ultrasonic treatment.
- 제 8 항에 있어서,The method of claim 8,상기 수산화나트륨(NaOH) 수용액은 0.1M 내지 0.2M의 농도로 첨가하는 것인 제조방법. The preparation method that the sodium hydroxide (NaOH) aqueous solution is added in a concentration of 0.1M to 0.2M.
- 제 8 항에 있어서,The method of claim 8,상기 초음파는 85℃ 내지 95℃에서 1.5시간 내지 2.5시간 동안 수행되는 것인 제조방법. The method of manufacturing the ultrasonic wave is carried out at 85 ℃ to 95 ℃ for 1.5 hours to 2.5 hours.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2019-0083267 | 2019-07-10 | ||
| KR20190083267 | 2019-07-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2021006684A1 true WO2021006684A1 (en) | 2021-01-14 |
Family
ID=74115124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/KR2020/009065 WO2021006684A1 (en) | 2019-07-10 | 2020-07-10 | Method for preparation of ultrasonicated yeast extract having excellent inhibitory activity against skin cancer and skin cancer-inhibiting composition comprising ultrasonicated yeast extract prepared by same method |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR102448457B1 (en) |
| WO (1) | WO2021006684A1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991007091A1 (en) * | 1989-11-09 | 1991-05-30 | Donzis Byron A | Insoluble yeast extract |
| KR20040082060A (en) * | 2003-03-18 | 2004-09-24 | 주식회사 바이오프로젠 | Composition comprising soluble glucan oligomer from Saccharomyces cerevisiae IS2 for immune activation or prevention and treatment of cancer and the preparation method thereof |
| KR20170055327A (en) * | 2015-11-11 | 2017-05-19 | (주)엠앤씨생명과학 | Natural riposome comprising saccharomyces genus yeast extract, its preparation process, and food or pharmaceutical composition comprising it |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101069686B1 (en) | 2009-05-01 | 2011-10-05 | 주식회사 제이케이바이오테크 | A NOVEL Phellinus sp. STRAIN AND POLYSACCHARIDE THEREFROM HAVING ANTITUMOR AND IMMUNE ACTIVITY |
| KR101365735B1 (en) | 2012-04-19 | 2014-02-21 | 부산대학교 산학협력단 | Pharmaceutical composition for preventing or treating hematological malignancies including hexane extract of garlic fermented by yeast |
-
2020
- 2020-07-10 WO PCT/KR2020/009065 patent/WO2021006684A1/en active Application Filing
- 2020-07-10 KR KR1020200085180A patent/KR102448457B1/en active IP Right Grant
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991007091A1 (en) * | 1989-11-09 | 1991-05-30 | Donzis Byron A | Insoluble yeast extract |
| KR20040082060A (en) * | 2003-03-18 | 2004-09-24 | 주식회사 바이오프로젠 | Composition comprising soluble glucan oligomer from Saccharomyces cerevisiae IS2 for immune activation or prevention and treatment of cancer and the preparation method thereof |
| KR20170055327A (en) * | 2015-11-11 | 2017-05-19 | (주)엠앤씨생명과학 | Natural riposome comprising saccharomyces genus yeast extract, its preparation process, and food or pharmaceutical composition comprising it |
Non-Patent Citations (2)
| Title |
|---|
| DEJUAN, HUANG ET AL.: "The research for the extraction of yeast’s nucleic acid with [BMIM] BF4-H2O-KH2PO4 ionic liquid aqueous two-phase system", ADVANCED MATERIALS RESEARCH, vol. 455-456, 2012, pages 477 - 482 * |
| ELWAKKAD AMANY, GHONEUM MAMDOOH, EL-SAWI MAMDOUH, MOHAMED SAADIA IBRAHIM, GAMAL EL DIN AMINA A., PAN DEYU, ELQATTAN GHADA MAHMOUD,: "Baker’s yeast induces apoptotic effects and histopathological changes on skin tumors in mice", COGENT MEDICINE, vol. 5, no. 1, 1 January 2018 (2018-01-01), pages 1437673, XP055772404, DOI: 10.1080/2331205X.2018.1437673 * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210007900A (en) | 2021-01-20 |
| KR102448457B1 (en) | 2022-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10960040B2 (en) | Composition for preventing and treating muscle diseases or improving muscular function, containing platycodon grandiflorum extract | |
| CN101495108B (en) | Composition for the treatment of resistant cancers comprising oridonin | |
| CA2605651C (en) | Compositions and methods for treating or preventing overweight or obesity with zinc-charged protein fragments | |
| EP3804718A1 (en) | Use of 2,3,5-substituted thiophene compound to prevent, ameliorate, or treat breast cancers | |
| KR20210014231A (en) | Composition for prevention or treatment of muscular disorders or improvement of muscular functions comprising seaweeds extract | |
| KR102124986B1 (en) | Composition for prevention or treatment of muscular disorder or improvement of muscular functions comprising Leonurus japonicus extract or leonurine | |
| WO2017191856A1 (en) | Antidiabetic effect of gypenoside 75 | |
| WO2024048998A1 (en) | Composition for prevention, alleviation, or treatment of bone disease, containing salvianolic acid as active ingredient | |
| WO2021006684A1 (en) | Method for preparation of ultrasonicated yeast extract having excellent inhibitory activity against skin cancer and skin cancer-inhibiting composition comprising ultrasonicated yeast extract prepared by same method | |
| KR20200140749A (en) | Composition for improvement, treatment or prevention of muscular disorders, or improvement of muscular functions comprising Cudrania tricuspidata | |
| EP2341066B1 (en) | Peptide having anti-diabetic activity and use thereof | |
| WO2019098811A2 (en) | Composition for preventing, alleviating, or treating bone loss diseases, comprising cyclo(his-pro) (chp) | |
| EP3009013A1 (en) | Therapeutic and nutritional compositions for functional gastrointestinal disorders | |
| KR101574536B1 (en) | Composition for promoting growth comprising coumaric acid | |
| KR101729374B1 (en) | Pharmaceutical composition for preventing or treating pulmonary fibrosis | |
| KR20220166834A (en) | Composition for inhibiting cellular senescence and method for inhibiting cellular senescence | |
| WO2020017921A1 (en) | Pharmaceutical composition, for preventing or treating sarcopenia, containing salicornia europaea extract | |
| KR101830395B1 (en) | Composition comprising squalene for enhancement of muscle function and prevention of muscle damage | |
| WO2020209674A1 (en) | Pharmaceutical composition for preventing or treating obesity containing biglycan as active ingredient | |
| WO2022098192A1 (en) | Composition for preventing or treating cachexia comprising medicinal herb complex extract | |
| KR20190110204A (en) | Kyung-ok-go having high acceptability and anti-diabetes activity adding the silk of zea mays and pumpkin | |
| WO2023113278A1 (en) | Anti-stress composition comprising natural extract mixture, and use thereof | |
| WO2021060922A1 (en) | Composition for preventing or treating neuropathic pain, containing syringaresinol | |
| CN108175793A (en) | A kind of animal medicinal composition and its preparation method and application | |
| WO2021020857A1 (en) | Use of composition for prevention, alleviation or treatment of bone loss disorders, containing extracts of reynoutria japonica and cassiae cortex interior |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20836674 Country of ref document: EP Kind code of ref document: A1 |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 20836674 Country of ref document: EP Kind code of ref document: A1 |